Skip to main content
SpringerLink
Log in

The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

Patients with chronic lymphocytic leukemia (CLL) with 13q deletion as the sole cytogenetic abnormality usually have a favorable outcome, but the frequency of the 13q14 deletion and its impact on the outcome of other B-cell chronic lymphoproliferative disorders (BCLPDs) remain unclear. To further characterize this aberration, we investigated the prognostic significance of 13q deletion in 541 patients with BCLPDs. We performed fluorescence in situ hybridization (FISH) studies with 13q locus-specific LSI-D13S25 and LSI-RB1 probes. 52.1% of the patients with CLL harbored 13q deletion, which was significantly higher than that of other BCLPDs (p < 0.001). The size of 13q deletion was heterogeneous in both CLL and other BCLPDs. However, the distribution of cases with different deletion sizes showed no significant difference between the two groups. Whereas 13q deletion was a favorable prognostic factor in CLL, a large deletion of 13q was associated with poor prognosis in terms of time to first therapy (p = 0.020), progression-free survival (p = 0.05) and overall survival (p = 0.002) in BCLPD cases other than CLL. In conclusion, the deletion of 13q varied in size both in CLL and in other BCLPDs and adversely influenced the prognosis of patients with other BCLPDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

BCLPDs:

B-cell chronic lymphoproliferative disorders

I-FISH:

Interphase fluorescence in situ hybridization

CLL:

Chronic lymphocytic leukemia

TTFT:

Time to first therapy

PFS:

Progression-free survival

OS:

Overall survival

SMZL:

Spleen marginal zone lymphoma

HCL:

Hairy cell lymphoma

WM:

Waldenström macroglobulinemia

MALT:

Mucosa-associated lymphoid tissue lymphoma

BMI:

Bone marrow involvement

NMZL:

Nodal marginal zone lymphoma

FL:

Follicular lymphoma

References

  1. Wong KF, Chan JK. Cytogenetic abnormalities in chronic B-cell lymphoproliferative disorders in Chinese patients. Cancer Genet Cytogenet. 1999;111:55–60.

    Article  CAS  PubMed  Google Scholar 

  2. Soubeyran I, de Mascarel A. Small B-cell lymphoproliferative disorders: an overview of diagnostic approach. Crit Rev Oncol Hematol. 2000;35:3–11.

    Article  CAS  PubMed  Google Scholar 

  3. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    Article  CAS  PubMed  Google Scholar 

  4. Mehes G. Chromosome abnormalities with prognostic impact in B-cell chronic lymphocytic leukemia. Pathol Oncol Res. 2005;11:205–10.

    Article  CAS  PubMed  Google Scholar 

  5. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Can Res. 2008;68:1012–21.

    Article  CAS  Google Scholar 

  6. Parker H, Rose-Zerilli MJ, Parker A, Chaplin T, Wade R, Gardiner A, et al. 13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia. Leukemia. 2011;25:489–97.

    Article  CAS  PubMed  Google Scholar 

  7. Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E, et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood. 2001;97:2098–104.

    Article  CAS  PubMed  Google Scholar 

  8. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Orlandi EM, Bernasconi P, Pascutto C, Giardini I, Cavigliano PM, Boni M, et al. Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase-FISH. Hematol Oncol. 2013;31:136–42.

    Article  CAS  PubMed  Google Scholar 

  10. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA. 2005;102:13944–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007;109:4944–51.

    Article  CAS  PubMed  Google Scholar 

  12. Ouillette P, Collins R, Shakhan S, Li J, Li C, Shedden K, et al. The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clin Cancer Res. 2011;17:6778–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 1999;10:1419–32.

  14. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. An G, Xu Y, Shi L, Shizhen Z, Deng S, Xie Z, et al. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value. Haematologica. 2014;99:353–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21:2148–56.

    Article  PubMed  Google Scholar 

  17. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood. 2000;95:1925–30.

    CAS  PubMed  Google Scholar 

  18. Bentz M, Plesch A, Bullinger L, Stilgenbauer S, Ott G, Muller-Hermelink HK, et al. t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia. Genes Chromosom Cancer. 2000;27:285–94.

    Article  CAS  PubMed  Google Scholar 

  19. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia. 2007;21:2442–51.

    Article  CAS  PubMed  Google Scholar 

  20. Qiu HX, Xu W, Cao XS, Zhou M, Shen YF, Xu YL, et al. Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leukemia Lymphoma. 2008;49:1887–92.

    Article  CAS  PubMed  Google Scholar 

  21. Dal Bo M, Rossi FM, Rossi D, Deambrogi C, Bertoni F, Del Giudice I, et al. 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. Genes Chromosom Cancer. 2011;50:633–43.

    Article  Google Scholar 

  22. Mian M, Rinaldi A, Mensah AA, Rossi D, Ladetto M, Forconi F, et al. Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. Hematol Oncol. 2012;30:46–9.

    Article  CAS  PubMed  Google Scholar 

  23. Huang SJ, Gillan TL, Gerrie AS, Hrynchak M, Karsan A, Ramadan K, et al. Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada. Genes Chromosom Cancer. 2016;55:16–24.

    Article  CAS  PubMed  Google Scholar 

  24. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 2004;430:797–802.

    Article  CAS  PubMed  Google Scholar 

  25. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene. 2006;25:746–55.

    Article  CAS  PubMed  Google Scholar 

  26. Hernandez JA, Rodriguez AE, Gonzalez M, Benito R, Fontanillo C, Sandoval V, et al. A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. Haematologica. 2009;94:364–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This publication was funded by the Chinese Academy of Medical Sciences and Peking Union Medical College.

Author information

Author notes

  1. Shuhua Yi and Heng Li contributed equally to this work.

Authors and Affiliations

  1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 288, Nanjing Road, Heping District, Tianjin, 300020, China

    Shuhua Yi, Heng Li, Zengjun Li, Wenjie Xiong, Huimin Liu, Wei Liu, Rui Lv, Zhen Yu, Dehui Zou, Yan Xu, Gang An & Lugui Qiu

Authors
  1. Shuhua Yi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heng Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zengjun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenjie Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Huimin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rui Lv
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhen Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Dehui Zou
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Gang An
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lugui Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Data collection was by SY, HL, WX, HL, SZ, WL, RL. SY, HL, CL, YX, GA, HW, KR performed analyses. SY, HL, ZL, ZY, DZ, LQ interpreted results of analyses. All authors prepared, reviewed and gave critical input into each stage of the manuscript.

Corresponding authors

Correspondence to Zengjun Li or Lugui Qiu.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Ethics Review Boards of Institute of Hematology and Blood Disease Hospital due to its retrospective character.

Consent for publication

Not applicable.

Availability of data and materials

Data are available on request from the authors, due to the fact that they contain treatment-specific information they may not be uploaded on a public shared base.

Funding

This work is supported by grants from the National Science and Technology Supporting Program (2014BAI09B12), the National Natural Science Foundation of China (81370632 and 81400092), the Fundamental Application and Advanced Technology Research Program of Tianjin (15JCYBJC27900).

Conflict of interest

The authors declare no competing financial interests.

Electronic supplementary material

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yi, S., Li, H., Li, Z. et al. The prognostic significance of 13q deletions of different sizes in patients with B-cell chronic lymphoproliferative disorders: a retrospective study. Int J Hematol 106, 418–425 (2017). https://doi.org/10.1007/s12185-017-2240-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2240-2

Keywords

Search

Navigation